A class action lawsuit has been filed against uniQure following the company's announcement that the FDA no longer agrees that data from Phase I/II studies of its gene therapy AMT-130 for Huntington's disease is sufficient for a Biologics License Application. This unexpected regulatory setback caused uniQure's stock to drop nearly 50% on November 3, 2025. Investors who purchased uniQure securities during the relevant period may seek to join the lawsuit, which alleges securities fraud or other unlawful practices by the company and its officers. The case highlights risks tied to regulatory approvals in biotech investing.
A regional nonprofit health plan reduced its Transparency in Coverage machine-readable file (MRF) production time from 45 days to less than 24 hours by integrating TALON's platform directly with its claims administration system. This eliminated a com...
ASUS has introduced two new Chromebooks in the US market: the budget-friendly CM15 laptop and the versatile CM32 Detachable 2-in-1 device. Both run on the MediaTek Kompanio 540 processor, offer up to 12 hours of battery life, and feature military-gra...
Slate Medicines, a biotech firm focused on migraine treatments, has appointed Mark W. Hahn to its Board of Directors. Hahn brings over 25 years of experience in life sciences, including leading companies through financial milestones and FDA approvals...
Goldman Sachs reported robust Q2 FY2026 results, with net earnings growing at an annualized rate of 38%. The firm raised $31 billion in private credit and saw a 130% year-over-year surge in equity underwriting revenues, driven by major deals and IPO ...
The Bitwise Bitcoin ETF (BITB) features competitive fees and tight trading spreads comparable to industry leaders like IBIT and FBTC. Despite strong execution on cost and trading efficiency, BITB's market share and asset growth have stalled due to li...
